Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 678152
                    [Title] => Roche bares positive results of breast cancer drug
                    [Summary] => 
BASEL, Switzerland — Roche has announced the topline results of its first randomized trial of trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer.
                    [DatePublished] => 2011-04-21 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 595084
                    [Title] => Roche submits US FDA application for 'T-DM1'
                    [Summary] => 
Roche announced recently that it submitted a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for trastuzumab-DM1 (T-DM1) in people with advanced HER2-positive breast cancer who have previously received multiple HER2-targeted medicines and chemotherapies.
                    [DatePublished] => 2010-07-22 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

DM1

Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 678152
                    [Title] => Roche bares positive results of breast cancer drug
                    [Summary] => 
BASEL, Switzerland — Roche has announced the topline results of its first randomized trial of trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer.
                    [DatePublished] => 2011-04-21 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 595084
                    [Title] => Roche submits US FDA application for 'T-DM1'
                    [Summary] => 
Roche announced recently that it submitted a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for trastuzumab-DM1 (T-DM1) in people with advanced HER2-positive breast cancer who have previously received multiple HER2-targeted medicines and chemotherapies.
                    [DatePublished] => 2010-07-22 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

abtest

Roche bares positive results of breast cancer drug

April 21, 2011 - 12:00am

BASEL, Switzerland — Roche has announced the topline results of its first randomized trial of trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer.

Science and Environment

Roche submits US FDA application for 'T-DM1'

July 22, 2010 - 12:00am

Roche announced recently that it submitted a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for trastuzumab-DM1 (T-DM1) in people with advanced HER2-positive breast cancer who have...

Science and Environment